Cardiothoracic & vascular anesthesia
Effect of Dexmedetomidine on Postoperative Renal Function in Patients Undergoing Cardiac Valve Surgery Under Cardiopulmonary Bypass: A Randomized Clinical Trial
Authors' conclusion
Dexmedetomidine may be considered as a way to reduce the incidence and severity of postoperative AKI in patients undergoing cardiac valve surgery under cardiopulmonary bypass.
Study context
- Population
- Patients scheduled for cardiac valve replacement or valvuloplasty under cardiopulmonary bypass (CPB), university teaching tertiary hospital, January 2020–March 2021
- Participants
- 70 patients
- Comparison
- Dexmedetomidine 0.6 μg/kg/h IV vs normal saline
- Dn = 35
- Cn = 35reference
- Primary endpoint
- Incidence of acute kidney injury (AKI)
Methodological detailssingle-centre
- Single-centre
Primary result
As reported in the abstract
P = 0.025
Secondary outcomes
MAP, 10 min before CPB (T1)
P = 0.013
MAP, 10 min after CPB (T2)
P < 0.001
MAP, 30 min after CPB (T3)
P = 0.004
Heart rate at T1
P = 0.022
Serum TNF-α, IL-6, C-reactive protein, cystatin C · after surgery (T4) and 24 h after surgery (T5)
- Significantly lower in D than C
Duration of mechanical ventilation, ICU stay, hospital stay
- Significantly shorter in D than C
Safety
Tachycardia, hypertension, nausea and vomiting
- Similar in D and C
Original publication
Effect of Dexmedetomidine on Postoperative Renal Function in Patients Undergoing Cardiac Valve Surgery Under Cardiopulmonary Bypass: A Randomized Clinical Trial. J Cardiothorac Vasc Anesth. Published 9 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →